Table 1.
Patients’ characteristics among those with and without respiratory progression.
| Variable | Total (n = 32) | Respiratory Progression (n = 7) | No Respiratory Progression (n = 25) | p |
|---|---|---|---|---|
| Demographic and comorbidities | ||||
| Age (years) | 67 (59–76) | 62 (59–75) | 68 (59–76) | 0.721 |
| Sex (female) | 43.8% (14) | 71.4% (5) | 36.0% (9) | 0.195 |
| Age-adjusted Charlson Index | 5 (3–6) | 3 (3–6) | 5 (4–7) | 0.324 |
| Obesity | 21.9% (7) | 28.6% (2) | 20.0% (5) | 1.000 |
| Arterial hypertension | 53.1% (17) | 28.6% (2) | 60.0% (15) | 0.209 |
| Diabetes mellitus | 34.4% (11) | 14.3% (1) | 40.0% (10) | 0.374 |
| Chronic pneumopathy | 40.6% (13) | 28.6% (2) | 44.0% (11) | 0.671 |
| Chronic heart failure | 31.3% (10) | 14.3% (1) | 36.0% (9) | 0.387 |
| Liver cirrhosis | 6.3% (2) | 0 | 8.0% (2) | 1.000 |
| Chronic renal failure | 37.5% (12) | 14.3% (1) | 44.0% (11) | 0.212 |
| Stroke | 3.1% (1) | 14.3% (1) | 0 | 0.219 |
| Chronic immunocompromise condition and medication | ||||
| Active cancer | 9.4% (3) | 14.3% (1) | 8.0% (1) | 1.000 |
| Hematological malignancy | 37.5% (12) | 85.7% (6) | 24.0% (6) | 0.006 |
| Solid organ transplantation | 46.9% (15) | 14.3% (1) | 56.0% (14) | 0.088 |
| Autoimmune disease | 32.3% (10) | 42.9% (3) | 29.2% (7) | 0.652 |
| Chronic corticoids | 43.8% (14) | 42.9% (3) | 44.0% (11) | 1.000 |
| Calcineurin inhibitors | 50.0% (16) | 14.3% (1) | 56.0% (14) | 0.088 |
| Antimetabolite | 37.5% (12) | 14.3% (1) | 44.0% (11) | 0.212 |
| mTOR | 6.3% (2) | 0 | 8.0% (2) | 1.000 |
| Monoclonal antibody | 37.5% (12) | 71.4% (5) | 28.0% (7) | 0.073 |
| Anti-CD20 antibody | 28.1% (9) | 57.1% (4) | 20.0% (5) | 0.149 |
| Immunization status | ||||
| Fully vaccinated | 93.8% (30) | 85.7% (6) | 96.0% (24) | 0.395 |
| Booster-dose | 53.3% (16/30) | 66.7% (4/6) | 50.0% (12/24) | 0.215 |
| Last dose (weeks) | 12 (9–29) | 14 (9–26) | 11 (8–30) | 0.823 |
| Serum positive anti-S IgG | 9.0% (2/22) | 0 (0/4) | 11.1% (2/18) | 1.000 |
| COVID-19 characteristics at sotrovimab infusion | ||||
| Symptoms onset (days) | 9 (5–15) | 16 (3–29) | 9 (5–13) | 0.220 |
| More than 14 days | 22.6% (7) | 57.1% (4) | 12.5% (3) | 0.029 |
| Dyspnea | 81.3% (26) | 85.7% (6) | 80.0% (20) | 1.000 |
| Cough | 81.3% (26) | 71.4% (5) | 84.0% (21) | 0.590 |
| Fever | 59.4% (19) | 57.1% (4) | 60.0% (15) | 1.000 |
| PaFi | 273 (236–315) | 200 (83–280) | 287 (243–315) | 0.054 |
| PaFi greater than 210 | 81.3% (26) | 42.9% (3) | 92.0% (23) | 0.005 |
| SaFi | 321 (297–351) | 182 (135–336) | 324 (300–354) | 0.036 |
| SaFi greater than 250 | 84.4% (27) | 42.9% (3) | 96.0% (24) | 0.004 |
| RT-PCR Ct | 21 (17–23) | 19 (17–20) | 21 (17–23) | 0.342 |
| Other COVID-19 treatments received during admission | ||||
| Corticoids | 96.9% (31) | 100% (7) | 96.0% (24) | 1.000 |
| Pulse-dose corticoid | 3.1% (1) | 0 | 4.0% (1) | 1.000 |
| Remdesivir | 50.0% (16) | 42.9% (3) | 52.0% (13) | 1.000 |
| Tocilizumab | 31.3% (10) | 57.1% (4) | 24.0% (6) | 0.165 |
| Other treatments | 9.4% (3) | 0 | 12.0% (3) | 1.000 |
Categorical variables are expressed as percentage (absolute values) and compared by means of Chi square test (or Fisher exact test when needed). Quantitative variables are expressed as median (interquartile range) and compared by means of Mann–Whitney’s U.